Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice.
Animals
Anticonvulsants
/ pharmacology
GABA Agents
/ pharmacology
Male
Mice, Inbred C57BL
Neuronal Plasticity
/ drug effects
Oculomotor Muscles
/ drug effects
Random Allocation
Retina
/ drug effects
Retinal Diseases
/ drug therapy
Tomography, Optical Coherence
Vigabatrin
/ pharmacology
Visual Fields
/ physiology
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
07 02 2020
07 02 2020
Historique:
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
14
4
2020
Statut:
ppublish
Résumé
Vigabatrin (VGB) is an effective antiepileptic that increases concentrations of inhibitory γ-aminobutyric acid (GABA) by inhibiting GABA transaminase. Reports of VGB-associated visual field loss limit its clinical usefulness, and retinal toxicity studies in laboratory animals have yielded conflicting results. We examined the functional and morphologic effects of VGB in C57BL/6J mice that received either VGB or saline IP from 10 to 18 weeks of age. Retinal structure and function were assessed in vivo by optical coherence tomography (OCT), ERG, and optomotor response. After euthanasia, retinas were processed for immunohistochemistry, and retinal GABA, and VGB quantified by mass spectrometry. No significant differences in visual acuity or total retinal thickness were identified between groups by optomotor response or optical coherence tomography, respectively. After 4 weeks of VGB treatment, ERG b-wave amplitude was enhanced, and amplitudes of oscillatory potentials were reduced. Dramatic rod and cone bipolar and horizontal cell remodeling, with extension of dendrites into the outer nuclear layer, was observed in retinas of VGB-treated mice. VGB treatment resulted in a mean 3.3-fold increase in retinal GABA concentration relative to controls and retinal VGB concentrations that were 20-fold greater than brain. No evidence of significant retinal thinning or ERG a- or b-wave deficits were apparent, although we describe significant alterations in ERG b-wave and oscillatory potentials and in retinal cell morphology in VGB-treated C57BL/6J mice. The dramatic concentration of VGB in retina relative to the target tissue (brain), with a corresponding increase in retinal GABA, offers insight into the pathophysiology of VGB-associated visual field loss.
Identifiants
pubmed: 32053727
pii: 2761291
doi: 10.1167/iovs.61.2.17
pmc: PMC7326505
doi:
Substances chimiques
Anticonvulsants
0
GABA Agents
0
Vigabatrin
GR120KRT6K
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Subventions
Organisme : NEI NIH HHS
ID : P30 EY016665
Pays : United States
Organisme : NIH HHS
ID : S10 OD018221
Pays : United States
Organisme : NEI NIH HHS
ID : T32 EY027721
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY027476
Pays : United States
Références
J Neurosci. 2000 Dec 15;20(24):9053-8
pubmed: 11124982
Am J Ophthalmol. 2000 Nov;130(5):691
pubmed: 11078870
Acta Neurol Scand Suppl. 2011;(192):36-47
pubmed: 22061179
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cell Physiol Biochem. 2016;40(5):831-846
pubmed: 27941319
Neuron. 2003 Mar 6;37(5):775-86
pubmed: 12628168
Mol Vis. 2008 Apr 25;14:782-806
pubmed: 18483561
Amino Acids. 2012 Nov;43(5):1979-93
pubmed: 22476345
Doc Ophthalmol. 2012 Jun;124(3):197-209
pubmed: 22426576
J Neurosci. 1999 Apr 1;19(7):2568-79
pubmed: 10087070
PLoS One. 2012;7(5):e37799
pubmed: 22629458
Exp Toxicol Pathol. 2015 Jan;67(1):13-20
pubmed: 25446799
Vis Neurosci. 2003 May-Jun;20(3):267-72
pubmed: 14570248
Pharmacol Res Perspect. 2019 Jan 07;7(1):e00456
pubmed: 30631446
Exp Toxicol Pathol. 1994 Aug;46(3):229-35
pubmed: 8000244
J Gen Physiol. 1985 Jun;85(6):911-31
pubmed: 2410539
Brain Res. 1978 Jun 16;148(2):530-5
pubmed: 306861
J Neurosci. 2009 Jan 7;29(1):106-17
pubmed: 19129389
Neurology. 2015 Aug 18;85(7):655-6
pubmed: 26283761
Ophthalmology. 2004 Oct;111(10):1935-42
pubmed: 15465561
Doc Ophthalmol. 2003 Nov;107(3):289-97
pubmed: 14711161
Vis Neurosci. 2003 Sep-Oct;20(5):535-42
pubmed: 14977332
Nat Rev Neurosci. 2002 Sep;3(9):715-27
pubmed: 12209120
Oncotarget. 2017 Sep 8;8(44):77696-77709
pubmed: 29100418
Exp Eye Res. 1975 Jul;21(1):79-87
pubmed: 1140222
Curr Eye Res. 2010 Jul;35(7):631-43
pubmed: 20597649
Epilepsy Res. 1993 Mar;14(3):245-55
pubmed: 8504795
Doc Ophthalmol. 2002 Mar;104(2):213-29
pubmed: 11999628
Acta Neurol Scand. 2012 Oct;126(4):219-28
pubmed: 22632110
Prog Retin Eye Res. 2005 May;24(3):395-431
pubmed: 15708835
Doc Ophthalmol. 2002 Mar;104(2):133-49
pubmed: 11999622
Dev Med Child Neurol. 2015 Jan;57(1):60-7
pubmed: 25145415
Ann Neurol. 2004 May;55(5):695-705
pubmed: 15122710
Transl Vis Sci Technol. 2015 Aug 25;4(4):9
pubmed: 26336634
Vision Res. 1988;28(2):203-10
pubmed: 3414006
Vision Res. 2000;40(6):579-89
pubmed: 10824262
Neurobiol Aging. 1981 Summer;2(2):133-41
pubmed: 7301039
Doc Ophthalmol. 2003 Nov;107(3):299-309
pubmed: 14711162
Epilepsia. 2001 May;42(5):609-15
pubmed: 11380567
Vision Res. 2001 Apr;41(8):1091-101
pubmed: 11301082
Neuroscience. 1996 Aug;73(4):1129-43
pubmed: 8809830
Acta Neurol Scand Suppl. 2011;(192):5-15
pubmed: 22061176
Prog Retin Eye Res. 1998 Jan;17(1):99-126
pubmed: 9537798
Neurosci Lett. 1995 Feb 9;185(2):119-22
pubmed: 7746501
Neurology. 2014 Dec 9;83(24):2262-8
pubmed: 25381295
J Inherit Metab Dis. 2013 May;36(3):401-10
pubmed: 22739941
Eur J Neurosci. 2005 Sep;22(5):1057-72
pubmed: 16176347
Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12156-60
pubmed: 16880381
Vision Res. 2004 Dec;44(28):3253-68
pubmed: 15535993
Neurochem Int. 2019 May;125:151-162
pubmed: 30822440
Ann Neurol. 2009 Jan;65(1):98-107
pubmed: 19194884
J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):787-9
pubmed: 11385015
J Neurophysiol. 2017 Jul 1;118(1):300-316
pubmed: 28424291
Acta Neurol Scand Suppl. 2011;(192):57-71
pubmed: 22061181
Doc Ophthalmol. 1993;85(2):135-50
pubmed: 7521824
Ophthalmology. 2001 Aug;108(8):1493-6; discussion 1497-8
pubmed: 11470707
Vision Res. 2000;40(13):1653-65
pubmed: 10814754
Vision Res. 1991;31(1):1-15
pubmed: 2006543
J Child Neurol. 2011 Jun;26(6):729-33
pubmed: 21343605
J Comp Neurol. 2007 Jan 10;500(2):286-98
pubmed: 17111373
Neurosci Lett. 1989 Mar 13;98(1):29-32
pubmed: 2710396
Int J Pharm. 2014 Oct 1;473(1-2):395-7
pubmed: 25062867
Vision Res. 2002 Apr;42(9):1081-7
pubmed: 11997047
Neuropediatrics. 2016 Aug;47(4):263-7
pubmed: 27104484
Eur J Neurosci. 2008 Apr;27(8):2177-87
pubmed: 18412635
Mol Cell Neurosci. 2010 Apr;43(4):414-21
pubmed: 20132888
Vis Neurosci. 2004 Jul-Aug;21(4):533-43
pubmed: 15579219
Vis Neurosci. 2011 Jan;28(1):95-108
pubmed: 20932357
Epilepsia. 2010 Dec;51(12):2423-31
pubmed: 21070215
Doc Ophthalmol. 2014 Oct;129(2):97-104
pubmed: 25008578
Doc Ophthalmol. 2015 Aug;131(1):1-11
pubmed: 25761928
Doc Ophthalmol. 2008 Sep;117(2):93-101
pubmed: 18188629
J Neurosci. 2002 May 15;22(10):4163-74
pubmed: 12019334
J Physiol. 1966 Aug;185(3):536-55
pubmed: 5918058
J Vis. 2011 May 23;11(6):
pubmed: 21606382
Epilepsia. 2016 Aug;57(8):e168-72
pubmed: 27344989
Nat Rev Neurosci. 2005 Mar;6(3):215-29
pubmed: 15738957
Vis Neurosci. 1994 May-Jun;11(3):519-32
pubmed: 8038126
Acta Ophthalmol (Copenh). 1980 Oct;58(5):712-25
pubmed: 7211260
Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1057-67
pubmed: 19412701
Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):784-91
pubmed: 15069568
J Neurosci Methods. 2015 Dec 30;256:91-105
pubmed: 26279344